Literature DB >> 24240936

Coronary artery bypass graft surgery vs percutaneous interventions in coronary revascularization: a systematic review.

Saswata Deb1, Harindra C Wijeysundera, Dennis T Ko, Hideki Tsubota, Samantha Hill, Stephen E Fremes.   

Abstract

IMPORTANCE: Ischemic heart disease is the leading cause of death globally. Coronary artery bypass graft (CABG) surgery and percutaneous coronary intervention (PCI) are the revascularization options for ischemic heart disease. However, the choice of the most appropriate revascularization modality is controversial in some patient subgroups.
OBJECTIVE: To summarize the current evidence comparing the effectiveness of CABG surgery and PCI in patients with unprotected left main disease (ULMD, in which there is >50% left main coronary stenosis without protective bypass grafts), multivessel coronary artery disease (CAD), diabetes, or left ventricular dysfunction (LVD). EVIDENCE REVIEW: A search of OvidSP MEDLINE, EMBASE, and Cochrane databases between January 2007 and June 2013, limited to randomized clinical trials (RCTs) and meta-analysis of trials and/or observational studies comparing CABG surgery with PCI was performed. Bibliographies of relevant studies were also searched. Mortality and major adverse cardiac and cerebrovascular events (MACCE, defined as all-cause mortality, myocardial infarction, stroke, and repeat revascularization) were reported wherever possible.
FINDINGS: Thirteen RCTs and 5 meta-analyses were included. CABG surgery should be recommended in patients with ULMD, multivessel CAD, or LVD, if the severity of coronary disease is deemed to be complex (SYNTAX >22) due to lower cardiac events associated with CABG surgery. In cases in which coronary disease is less complex (SYNTAX ≤22) and/or the patient is a higher surgical risk, PCI should be considered. For patients with diabetes and multivessel CAD, CABG surgery should be recommended as standard therapy irrespective of the severity of coronary anatomy, given improved long-term survival and lower cardiac events (5-year MACCE, 18.7% for CABG surgery vs 26.6% for PCI; P = .005). Overall, the incidence of repeat revascularization is higher after PCI, whereas stroke is higher after CABG surgery. Current literature emphasizes the importance of a heart-team approach that should consider coronary anatomy, patient characteristics, and local expertise in revascularization options. Literature pertaining to revascularization options in LVD is scarce predominantly due to LVD being an exclusion factor in most studies. CONCLUSIONS AND RELEVANCE: Both CABG surgery and PCI are reasonable options for patients with advanced CAD. Patients with diabetes generally have better outcomes with CABG surgery than PCI. In cases of ULMD, multivessel CAD, or LVD, CABG surgery should be favored in patients with complex coronary lesions and anatomy and PCI in less complicated coronary disease or deemed a high surgical risk. A heart-team approach should evaluate coronary disease complexity, patient comorbidities, patient preferences, and local expertise.

Entities:  

Mesh:

Year:  2013        PMID: 24240936     DOI: 10.1001/jama.2013.281718

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  67 in total

1.  How to differentiate the etiology of LV dysfunction as to whether it is "ischemic cardiomyopathy" or "dilated non-ischemic cardiomyopathy"? Invasive coronary and myocardial assessment is the approach of first choice.

Authors:  Sung Gyun Ahn; Habib Samady
Journal:  J Nucl Cardiol       Date:  2015-07-08       Impact factor: 5.952

2.  Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization.

Authors:  Nadia Bouabdallaoui; Susanna R Stevens; Torsten Doenst; Mark C Petrie; Nawwar Al-Attar; Imtiaz S Ali; Andrew P Ambrosy; Anna K Barton; Raymond Cartier; Alexander Cherniavsky; Pierre Demondion; Patrice Desvigne-Nickens; Robert R Favaloro; Sinisa Gradinac; Petra Heinisch; Anil Jain; Marek Jasinski; Jerome Jouan; Renato A K Kalil; Lorenzo Menicanti; Robert E Michler; Vivek Rao; Peter K Smith; Marian Zembala; Eric J Velazquez; Hussein R Al-Khalidi; Jean L Rouleau
Journal:  Circ Heart Fail       Date:  2018-11       Impact factor: 8.790

Review 3.  Optimal use of arterial grafts during current coronary artery bypass surgery.

Authors:  Suzuki Tomoaki
Journal:  Surg Today       Date:  2017-07-13       Impact factor: 2.549

4.  Coronary revascularization strategies in patients with multivessel disease: is it all about diabetes?

Authors:  Sergio Buccheri; Davide Capodanno
Journal:  Cardiovasc Diagn Ther       Date:  2017-06

5.  Coronary surgery in elderly: it is never too late.

Authors:  Pierpaolo Chivasso; Umberto Benedetto
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

6.  Perceiving one's heart condition to be cured following hospitalization for acute coronary syndromes: Implications for patient-provider communication.

Authors:  Molly E Waring; David D McManus; Stephenie C Lemon; Joel M Gore; Milena D Anatchkova; Richard H McManus; Arlene S Ash; Robert J Goldberg; Catarina I Kiefe; Jane S Saczynski
Journal:  Patient Educ Couns       Date:  2015-10-23

7.  A Combination of Drug-Eluting Stents and Bioresorbable Vascular Scaffolds in the Treatment of Multivessel Coronary Artery Disease.

Authors:  Ahmed Al-Mamary; Filippo Zilio; Massimo Napodano
Journal:  Sultan Qaboos Univ Med J       Date:  2016-08-19

Review 8.  [National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].

Authors:  K Werdan
Journal:  Herz       Date:  2016-09       Impact factor: 1.443

9.  Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase.

Authors:  I Marini; R Moschini; A Del Corso; U Mura
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

Review 10.  Vein graft failure: from pathophysiology to clinical outcomes.

Authors:  Margreet R de Vries; Karin H Simons; J Wouter Jukema; Jerry Braun; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2016-05-19       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.